Article thumbnail

Antithrombotic therapy in very elderly patients with atrial fibrillation: Is it enough to assess thromboembolic risk?

By Yutao Guo, Qiang Wu, Lu Zhang, Tingshu Yang, Ping Zhu, Wenqian Gao, Yuexiang Zhao and Meng Gao


Although attention has been given to thromboprophylaxis for atrial fibrillation (AF) in present treatment guidelines, practical, clinical antithrombotic therapy is poorly developed for very elderly patients. We reviewed the records of 105 consecutive patients with AF of mean age 85 years, to determine how the greatest benefits from antithrombotic therapy could be obtained in this group. The mean CHADS2 score in these patients was 3.1 ± 1.5. Before antithrombotic therapy, 21.0% of the patients had diseases with a risk of hemorrhage, 26.7% had diseases with a risk of thrombosis, and 8.6% had diseases with a risk of both hemorrhage and thrombosis. Moreover, 89 patients (84.8%) were receiving a single antiplatelet drug, 10 (9.5%) used aspirin plus clopidogrel, and six (5.7%) were taking an oral anticoagulant (OAC). Additionally, dual antiplatelet therapy was more commonly given to patients with permanent AF (paroxysmal and persistent versus permanent, 6.3% and 12.5% versus 30%, respectively, Chi-square = 8.4, P = 0.010). The incidence of adverse events was 25.7%, with thromboembolic events in 20.0% and hemorrhage in 5.7% of patients. There were no thromboembolic events in those patients taking OACs, but 33% of patients who took OACs had bleeding complications. It is difficult to choose appropriate antithrombotic strategies in very elderly patients. Both the thrombotic risk and the bleeding risk should be considered for helping such patients derive optimal benefit from thromboprophylaxis for AF

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation.
  2. An epidemiological survey of atrial fibrillation in China.
  3. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: A single-center, retrospective, observational study.
  4. (2003). Atrial fibrillation and the hypercoagulable state: From basic science to clinical practice. Pathophysiol Haemost Thromb.
  5. Contemporary management of atrial fibrillation: Update on anticoagulation and invasive management strategies. Mayo Clin
  6. International consensus on nomenclature and classification of atrial fibrillation.
  7. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA)
  8. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation.
  9. Relationship between left atrial appendage function and left atrial thrombus in patients with nonvalvular chronic atrial fibrillation and atrial flutter.
  10. Retrospective investigation of hospitalized patients with atrial fibrillation in mainland China.
  11. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: The Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE-W).
  12. Selecting patients with atrial fibrillation for anticoagulation stroke risk stratification in patients taking aspirin.
  13. (2009). Stroke: Atrial fibrillation, stroke prevention therapy and aging. Nat Rev Cardiol.
  14. (2009). Use of anticoagulants in elderly patients: Practical recommendations. Clin Interv Aging.
  15. Validation of clinical classification schemes for predicting stroke. Results form the National Registry of Atrial Fibrillation.
  16. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial.